Podcasts about neuroendocrine

Over the past several decades, neuroendocrine cancer diagnoses have increased significantly—raising an important question: Are these cancers becoming more common, or are we simply getting better at finding them? In this episode of NETWise, leading clinicians, researchers, and a patient share what the data—and real-world experience—reveal about this trend.Drawing on insights from global experts and patient perspectives, this conversation explores how advances in imaging, pathology, and research are reshaping what we know about neuroendocrine cancer—and why earlier recognition is changing the landscape of care.In this episode, you'll hear about:Why diagnoses have risen dramatically in recent decades—and why improved detection explains much of the increaseHow modern imaging, screening, and updated classification systems are helping doctors identify tumors earlier and more accuratelyThe environmental, biological, and social factors researchers are still working to understandWhy many tumors are now discovered incidentally, before symptoms appearHow earlier detection creates both new opportunities—and new questions—about screening and treatment decisionsA patient's personal story of diagnosis and how awareness can lead to earlier answers and better outcomesAs understanding grows, so does the ability to diagnose neuroendocrine cancer with greater precision—and to treat it more effectively. This episode brings clarity to what's behind the rising numbers and what that progress means for patients and families today.Whether you're a patient, caregiver, clinician, or advocate, this episode offers clear, accessible insights into the breakthroughs driving research forward. Please like, share, and subscribe. Your engagement helps us reach more patients and caregivers seeking reliable neuroendocrine cancer information—and supports NETRF's mission to expand research, awareness, and hope across the NET community. NET specialists included in this episodeUse our episode infographics to get a visual picture of some of the things we have discussed. Ulrich-Frank Pape, MDGastroenterologist, Asklepios Klinik St. Georg, Hamburg, Germany Arvind Dasari, MDGastrointestinal Medical Oncologist, MD Anderson Cancer Center Neil Renwick, MD, PhD, FRCPCAssistant Professor, Department of Pathology & Molecular Medicine, Queen's University(SEAMO New Clinician-Scientist Program) Nancy Joseph, MD, PhDProfessor of Surgical Pathology, University of California, San Francisco (UCSF) A special thank you to Jessica Ochoa for sharing her neuroendocrine cancer journey. Download a transcript of this episode. The post Episode 52: Why Is Neuroendocrine Cancer on the Rise? appeared first on NETRF.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JDA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until February 8, 2027.Catalysts for Enhanced Patient CARE In Neuroendocrine Neoplasms: Clinical Adoption of Rapidly Emerging Evidence on Novel Therapeutic Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Neuroendocrine Cancer Awareness Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from Boehringer Ingelheim Pharmaceuticals, Inc., Exelixis, Inc., and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JDA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until February 8, 2027.Catalysts for Enhanced Patient CARE In Neuroendocrine Neoplasms: Clinical Adoption of Rapidly Emerging Evidence on Novel Therapeutic Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Neuroendocrine Cancer Awareness Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from Boehringer Ingelheim Pharmaceuticals, Inc., Exelixis, Inc., and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

Send a textMorning Prayer (No Condemnation; Endocrine Cancers - Pancreas, Adrenal, Pituitary, Parathyroid, Neuroendocrine; Persecuted Christians; If God is For Us!)Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peace aimingforjesus.com YouTube Channel https://www.youtube.com/@aimingforjesus5346 Instagram https://www.instagram.com/aiming_for_jesus/ Threads https://www.threads.com/@aiming_for_jesus X https://x.com/AimingForJesus Tik Tok https://www.tiktok.com/@aiming.for.jesus

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/PBT865. EBAC/CME credit will be available until 7 January 2027.From Poor Prognosis to Emerging Clinical Potential: A Visual Journey of Targeted Therapy Innovation in Extrapulmonary Neuroendocrine Carcinomas In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/PBT865. EBAC/CME credit will be available until 7 January 2027.From Poor Prognosis to Emerging Clinical Potential: A Visual Journey of Targeted Therapy Innovation in Extrapulmonary Neuroendocrine Carcinomas In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/PBT865. EBAC/CME credit will be available until 7 January 2027.From Poor Prognosis to Emerging Clinical Potential: A Visual Journey of Targeted Therapy Innovation in Extrapulmonary Neuroendocrine Carcinomas In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/PBT865. EBAC/CME credit will be available until 7 January 2027.From Poor Prognosis to Emerging Clinical Potential: A Visual Journey of Targeted Therapy Innovation in Extrapulmonary Neuroendocrine Carcinomas In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/PBT865. EBAC/CME credit will be available until 7 January 2027.From Poor Prognosis to Emerging Clinical Potential: A Visual Journey of Targeted Therapy Innovation in Extrapulmonary Neuroendocrine Carcinomas In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/PBT865. EBAC/CME credit will be available until 7 January 2027.From Poor Prognosis to Emerging Clinical Potential: A Visual Journey of Targeted Therapy Innovation in Extrapulmonary Neuroendocrine Carcinomas In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/PBT865. EBAC/CME credit will be available until 7 January 2027.From Poor Prognosis to Emerging Clinical Potential: A Visual Journey of Targeted Therapy Innovation in Extrapulmonary Neuroendocrine Carcinomas In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/PBT865. EBAC/CME credit will be available until 7 January 2027.From Poor Prognosis to Emerging Clinical Potential: A Visual Journey of Targeted Therapy Innovation in Extrapulmonary Neuroendocrine Carcinomas In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Tracy, a stage 2 Neuroendocrine Cancer Thriver shares her story of holistic healing.Tracy underwent some routine screening in July 2022 and a tumor was found in her lung. It was a rare form of neuroendocrine cancer. She immediately searched for natural ways to heal cancer when she found Chris Wark who led her to HealingStrong.In September 2022, due to dead tissue, Tracy had a partial lung removal, bi-lobectomy, and skipped chemotherapy. She jumped in and changed her mindset, nutrition, supplementation, and was intentional with prayer. She went from anxiety and panic to having peace in God's plan.Tracy recently had her 3 year scans and no evidence of cancer was found. HealingStrong's mission is to educate, equip and empower our group leaders and group participants through their journey with cancer or other chronic illnesses, and know there is HOPE. We bring this hope through educational materials, webinars, guest speakers, conferences, community small group support and more.Please take advantage of our FREE resources below to help you along your health and healing journey: Support Group Directory Holistic Curriculum - Participant Guide Support Our Mission - Donate Additional Health Resources Listen to Previous Episodes Website: healingstrong.org

Research has been at the heart of NETRF's mission for 20 years—and patients are the reason that work matters. Every study we fund is designed to move the field forward and improve how people with neuroendocrine cancer live, feel, and are treated. In this special episode of NETWise, we're bringing the 2025 NETRF Neuroendocrine Cancer […] The post NETWise Episode 50: The Year in Review 2025: Neuroendocrine Cancer Research and Clinical Progress appeared first on NETRF.

Authors Drs. Jessica Ross and Alissa Cooper share insights into their JCO PO article, "Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine Carcinomas"  Host Dr. Rafeh Naqash and Drs. Ross and Cooper discuss the landscape of Delta-like ligand 3 (DLL3) and seizure-related homolog protein 6 (SEZ6) across NECs from eight different primary sites. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO PO and an Associate Professor at the OU Health Stephenson Cancer Center. Today, I'm excited to be joined by Dr. Jessica Ross, third-year medical oncology fellow at the Memorial Sloan Kettering Cancer Center, as well as Dr. Alissa Cooper, thoracic medical oncologist at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School. Both are first and last authors of the JCO Precision Oncology article entitled "Clinical and Pathologic Landscapes of Delta-like Ligand 3 and Seizure-Related Homolog Protein 6 or SEZ6 Protein Expression in Neuroendocrine Carcinomas." At the time of this recording, our guest disclosures will be linked in the transcript. Jessica and Alissa, welcome to our podcast, and thank you for joining us today. Dr. Jessica Ross: Thanks very much for having us. Dr. Alissa Cooper: Thank you. Excited to be here. Dr. Rafeh Naqash: It's interesting, a couple of days before I decided to choose this article, one of my GI oncology colleagues actually asked me two questions. He said, "Rafeh, do you know how you define DLL3 positivity? And what is the status of DLL3 positivity in GI cancers, GI neuroendocrine carcinomas?" The first thing I looked up was this JCO article from Martin Wermke. You might have seen it as well, on obrixtamig, a phase 1 study, a DLL3 bi-specific T-cell engager. And they had some definitions there, and then this article came along, and I was really excited that it kind of fell right in place of trying to understand the IHC landscape of two very interesting targets. Since we have a very broad and diverse audience, especially community oncologists, trainees, and of course academic clinicians and some people who are very interested in genomics, we'll try to make things easy to understand. So my first question for you, Jessica, is: what is DLL3 and SEZ6 and why are they important in neuroendocrine carcinomas? Dr. Jessica Ross: Yeah, good question. So, DLL3, or delta-like ligand 3, is a protein that is expressed preferentially on the tumor cell surface of neuroendocrine carcinomas as opposed to normal tissue. It is a downstream target of ASCL1, and it's involved in neuroendocrine differentiation, and it's an appealing drug target because it is preferentially expressed on tumor cell surfaces. And so, it's a protein, and there are several drugs in development targeting this protein, and then Tarlatamab is an approved bi-specific T-cell engager for the treatment of extensive-stage small cell lung cancer in the second line. SEZ6, or seizure-like homolog protein 6, is a protein also expressed on neuroendocrine carcinoma cell surface. Interestingly, so it's expressed on neuronal cells, but its exact role in neuroendocrine carcinomas and oncogenesis is actually pretty poorly understood, but it was identified as an appealing drug target because, similarly to DLL3, it's preferentially expressed on the tumor cell surface. And so this has also emerged as an appealing drug target, and there are drugs in development, including antibody-drug conjugates, targeting this protein for that reason. Dr. Alissa Cooper: Over the last 10 to 15 years or so, there's been an increasing focus on precision oncology, finding specific targets that actually drive the cancer to grow, not just within lung cancer but in multiple other primary cancers. But specifically, at least speaking from a thoracic oncology perspective, the field of non-small cell lung cancer has completely exploded over the past 15 years with the discovery of driver oncogenes and then matched targeted therapies. Within the field of neuroendocrine carcinomas, including small cell lung cancer but also other high-grade neuroendocrine carcinomas, there has not been the same sort of progress in terms of identifying targets with matched therapies. And up until recently, we've sort of been treating these neuroendocrine malignancies kind of as a monolithic disease process. And so recently, there's been sort of an explosion of research across the country and multiple laboratories, multiple people converging on the same open questions about why might patients with specific tumor biologies have different kind of responses to different therapies. And so first this came from, you know, why some patients might have a good response to chemo and immunotherapy, which is the first-line approved therapy for small cell lung cancer, and we also sort of extrapolate that to other high-grade neuroendocrine carcinomas. What's the characteristic of that tumor biology? And at the same time, what are other targets that might be identifiable? Just as Jesse was saying, they're expressed on the cell surface, they're not necessarily expressed in normal tissue. Might this be a strategy to sort of move forward and create smarter therapies for our patients and therefore move really into a personalized era for treatment for each patient? And that's really driving, I think, a lot of the synthesis of this work of not only the development of multiple new therapies, but really understanding which tumor might be the best fit for which therapy. Dr. Rafeh Naqash: Thank you for that explanation, Alissa. And as you mentioned, these are emerging targets, some more further along in the process with approved drugs, especially Tarlatamab. And obviously, DLL3 was something identified several years back, but drug development does take time, and readout for clinical trials takes time. Could you, for the sake of our audience, try to talk briefly about the excitement around Tarlatamab in small cell lung cancer, especially data that has led to the FDA approval in the last year, year and a half? Dr. Alissa Cooper: Sure. Yeah, it's really been an explosion of excitement over, as you're saying, the last couple of years, and work really led by our mentor, Charlie Rudin, had identified DLL3 as an exciting target for small cell lung cancer specifically but also potentially other high-grade neuroendocrine malignancies. Tarlatamab is a DLL3-targeting bi-specific T-cell engager, which targets DLL3 on the small cell lung cancer cells as well as CD3 on T cells. And the idea is to sort of introduce the cancer to the immune system, circumventing the need for MHC class antigen presentation, which that machinery is typically not functional in small cell lung cancer, and so really allowing for an immunomodulatory response, which had not really been possible for most patients with small cell lung cancer prior to this. Tarlatamab was tested in a phase 2 registrational trial of about 100 patients and demonstrated a response rate of 40%, which was very exciting, especially compared with other standard therapies which were available for small cell lung cancer, which are typically cytotoxic therapies. But most excitingly, more than even the response rate, I think, in our minds was the durability of response. So patients whose disease did have a response to Tarlatamab could potentially have a durable response lasting a number of months or even over a year, which had previously not ever been seen in this in the relapsed/refractory setting for these patients. I think the challenge with small cell lung cancer and other high-grade neuroendocrine malignancies is that a response to therapy might be a bit easier to achieve, but it's that durability. The patient's tumors really come roaring back quite aggressively pretty quickly. And so this was sort of the most exciting prospect is that durability of response, that long potential overall survival tail of the curve really being lifted up. And then most recently at ASCO this year, Dr. Rudin presented the phase 3 randomized controlled trial which compared Tarlatamab to physician's choice of chemotherapy in a global study. And the choice of chemotherapy did vary depending on the part of the world that the patients were enrolled in, but in general, it was a really markedly positive study for response rate, for progression-free survival, and for overall survival. Really exciting results which really cemented Tarlatamab's place as the standard second-line therapy for patients with small cell lung cancer whose disease has progressed on first-line chemo-immunotherapy. So that has been very exciting. This drug was FDA approved in May of 2024, and so has been used extensively since then. I think the adoption has been pretty widespread, at least in the US, but now in this global trial that was just presented, and there was a corresponding New England Journal paper, I think really confirms that this is something we really hopefully can offer to most of our patients. And I think, as we all know, that this therapy or other therapies like it are also being tested potentially in the first-line setting. So there was data presented with Tarlatamab incorporated into the maintenance setting, which also showed exciting results, albeit in a phase 1 trial, but longer overall survival than we're used to seeing in this patient population. And we await results of the study that is incorporating Tarlatamab into the induction phase with chemotherapy as well. So all of this is extraordinarily exciting for our patients to sort of move the needle of how many patients we can keep alive, feeling functional, feeling well, for as long as possible. Dr. Rafeh Naqash: Very exciting session at ASCO. I was luckily one of the co-chairs for the session that Dr. Rudin presented it, and I remember somebody mentioning there was more progress seen in that session for small cell lung cancer than the last 30, 35 years for small cell, very exciting space and time to be in as far as small cell lung cancer. Now going to this project, Jessica, since you're the first author and Alissa's the last, I'm assuming there was a background conversation that you had with Alissa before you embarked on this project as an idea. So could you, again, for other trainees who are interested in doing research, and it's never easy to do research as a resident and a fellow when you have certain added responsibilities. Could you give us a little bit of a background on how this started and why you wanted to look at this question? Dr. Jessica Ross: Yeah, sure. So, as with many exciting research concepts, I think a lot of them are derived from the clinic. And so I think Alissa and I both see a good number of patients with small cell, large cell lung cancer, and then high-grade neuroendocrine carcinomas. And so I think this was really born out of a basic conversation of we have these drugs in development targeting these two proteins, DLL3 and SEZ6, but really what is the landscape of cancers that express these proteins and who are the patients that really might benefit from these exciting new therapies. And of course, there was some data out there, but sort of less than one would imagine in terms of, you know, neuroendocrine carcinomas can really come from anywhere in the body. And so when you're seeing a patient with small cell of the cervix, for example, like what are the chances that their cancer expresses DLL3 or expresses SEZ6? So it was really derived from this pragmatic, clinically oriented question that we had both found ourselves thinking about, and we were lucky enough at MSK, we had started systematically staining patients' tumors for DLL3, tumors that are high-grade neuroendocrine carcinomas, and then we had also more recently started staining for SEZ6 as well. And so we had this nice prospectively collected dataset with which to answer this question. Dr. Rafeh Naqash: Excellent. And Alissa, could you try to go into some of the details around which patients you chose, how many patients, what was the approach that you selected to collect the data for this project? Dr. Alissa Cooper: This is perhaps a strength but also maybe a limitation of this dataset is, as Jesse alluded to, our pathology colleagues are really the stars of this paper here because we were lucky enough at MSK that they were really forethinking. They are absolute experts in the field and really forward-thinking people in terms of what information might be needed in the future to drive treatment decision-making. And so, as Jesse had said, small cell lung cancer tumor samples reflexively are stained for DLL3 and SEZ6 at MSK if there's enough tumor tissue. The other high-grade neuroendocrine carcinomas, those stains are performed upon physician request. And so that is a bit of a mixed bag in terms of the tumor samples we were able to include in this dataset because, you know, upon physician request depends on a number of factors, but actually at MSK, a number of physicians were requesting these stains to be done on their patients with high-grade neuroendocrine cancers of of other histologies. So we looked at all tumor samples with a diagnosis of high-grade neuroendocrine carcinoma of any histology that were stained for these two stains of interest. You know, I can let Jesse talk a bit more about the methodology. She was really the driver of this project. Dr. Jessica Ross: Yeah, sure. So we had 124 tumor samples total. All of those were stained for DLL3, and then a little less than half, 53, were stained for SEZ6. As Alissa said, they were from any primary site. So about half of them were of lung origin, that was the most common primary site, but we included GI tract, head and neck, GU, GYN, even a few tumors of unknown origin. And again, that's because I think a lot of these trials are basket trials that are including different high-grade neuroendocrine carcinomas no matter the primary site. And so we really felt like it was important to be more comprehensive and inclusive in this study. And then, methodologically, we also defined positivity in terms of staining of these two proteins as anything greater than or equal to 1% staining. There's really not a defined consensus of positivity when it comes to these two novel targets and staining for these two proteins. But in the Tarlatamab trials, for some of the correlative work that's been done, they use that 1% cutoff, and we just felt like being consistent with that and also using a sort of more pragmatic yes/no cutoff would be more helpful for this analysis. Dr. Alissa Cooper: And that was a point of discussion, actually. We had contemplated multiple different schemas, actually, for how to define thresholds of positivity. And I know you brought up that question before, what does it mean to be DLL3 positive or DLL3 high? I think you were alluding to prior that there was a presentation of obrixtamig looking at extra-pulmonary neuroendocrine carcinomas, and they actually divvied up the results between DLL3 50% or greater versus DLL3 low under 50%. And they actually did demonstrate differential efficacy certainly, but also some differential safety as well, which is very provocative and that kind of analysis has not been presented for other novel therapies as far as I'm aware. I could be wrong, but as far as I'm aware, that was sort of the first time that we saw a systematic presentation of considering patients to be, quote unquote, "high" or "low" in these sort of novel targets. I think it is important because the label for Tarlatamab does not require any DLL3 expression at all, actually. So it's not hinging upon DLL3 expression. They depend on the fact that the vast majority of small cell lung cancer tumors do express DLL3, 85% to 90% is what's been demonstrated in a few studies. And so, there's not prerequisite testing needed in that regard, but maybe for these extra-pulmonary, other histology neuroendocrine carcinomas, maybe it does matter to some degree. Dr. Rafeh Naqash: Definitely agree that this evolving landscape of trying to understand whether an expression for something actually really does correlate with, whether it's an immune cell engager or an antibody-drug conjugate is a very evolving and dynamically moving space. And one of the questions that I was discussing with one of my friends was whether IHC positivity and the level of IHC positivity, as you've shown in one of those plots where you have double positive here on the right upper corner, you have the double negative towards the left lower, whether that somehow determines mRNA expression for DLL3. Obviously, that was not the question here that you were looking at, but it does kind of bring into question certain other aspects of correlations, expression versus IHC. Now going to the figures in this manuscript, very nicely done figures, very easy to understand because I've done the podcast for quite a bit now, and usually what I try to do first is go through the figures before I read the text, and and a lot of times it's hard to understand the figures without reading the text, but in your case, specifically the figures were very, very well done. Could you give us an overview, a quick overview of some of the important results, Jessica, as far as what you've highlighted in the manuscript? Dr. Jessica Ross: Sure. So I think the key takeaway is that, of the tumors in our cohort, the majority were positive for DLL3 and positive for SEZ6. So about 80% of them were positive for DLL3 and 80% were positive for SEZ6. About half of the tumors were stained for both proteins, and about 65% of those were positive as well. So I think if there's sort of one major takeaway, it's that when you're seeing a patient with a high-grade neuroendocrine carcinoma, the odds are that their tumor will express both of these proteins. And so that can sort of get your head thinking about what therapies they might be eligible for. And then we also did an analysis of some populations of interest. So for example, we know that non-neuroendocrine pathologies can transform into neuroendocrine tumors. And so we specifically looked at that subset of patients with transformed tumors, and those were also- the majority of them were positive, about three-quarters of them were positive for both of these two proteins. We looked at patients with brain met samples, again, about 70% were positive. And then I'd say the last sort of population of interest was we had a subset of 10 patients who had serial biopsies stained for either DLL3 or SEZ6 or both. In between the two samples, these patients were treated with chemotherapy. They were not treated with targeted therapy, but interestingly, in the majority of cases, the testing results were concordant, meaning if it was DLL3 positive to begin with, it tended to remain DLL3 positive after treatment. And so I think that's important as well as we think about, you know, a patient who maybe had DLL3 testing done before they received their induction chemo-IO, we can somewhat confidently say that they're probably still DLL3 positive after that treatment. And then finally, we did do a survival analysis among specifically the patients with lung neuroendocrine carcinomas. We looked at whether DLL3 expression affected progression-free survival on first-line platinum-etoposide, and then we looked at did it affect overall survival. And we found that it did not have an impact or the median progression-free survival was similar whether you were DLL3 positive or negative. But interestingly, with overall survival, we found that DLL3 positivity actually correlated with slightly improved overall survival. These were small numbers, and so, you know, I think we have to interpret this with caution, for sure, but it is interesting. I think there may be something to the fact that five of the patients who were DLL3 positive were treated with DLL3-targeting treatments. And so this made me think of, like in the breast cancer world, for example, if you have a patient with HER2-positive disease, it initially portended worse prognosis, more aggressive disease biology, but on the other hand, it opens the door for targeted treatments that actually now, at least with HER2-positive breast cancer, are associated with improved outcomes. And so I think that's one finding of interest as well. Dr. Rafeh Naqash: Definitely proof-of-concept findings here that you guys have in the manuscript. Alissa, if I may ask you, what is the next important step for a project like this in your mind? Dr. Alissa Cooper: Jesse has highlighted a couple of key findings that we hope to move forward with future investigative studies, not necessarily in a real-world setting, but maybe even in clinical trial settings or in collaboration with sponsors. Are these biomarkers predictive? Are they prognostic? You know, those are still- we have some nascent data, data has been brewing, but I think that we we still don't have the answers to those open questions, which I think are critically important for determining not only clinical treatment decision-making, but also our ability to understand sequencing of therapies, prioritization of therapies. I think a prospective, forward-looking project, piggybacking on that paired biopsy, you know, we had a very small subset of patients with paired biopsies, but a larger subset or cohort looking at paired biopsies where we can see is there evolution of these IHC expression, even mRNA expression, as you're saying, is there differential there? Are there selection pressures to targeted therapies? Is there upregulation or downregulation of targets in response not just to chemotherapy, but for example, for other sort of ADCs or bi-specific T-cell engagers? I think those are going to be critically important future studies which are going to be a bit challenging to do, but really important to figure out this key clinical question of sequencing, which we're all contemplating in our clinics day in and day out. If you have a patient, and these patients often can be sick quite quickly, they might have one shot of what's the next treatment that you're going to pick. We can't guarantee that every patient is going to get to see every therapy. How can you help to sort of answer the question of like what should you offer? So I think that's the key question sort of underlying any future work is how predictive or prognostic are these biomarkers? What translational or correlative studies can we do on the tissue to understand clinical treatment decision-making? I think those are the key things that will unfold in the next couple of years. Dr. Rafeh Naqash: The last question for you, Alissa, that I have is, you are fairly early in your career, and you've accomplished quite a lot. One of the most important things that comes out from this manuscript is your mentorship for somebody who is a fellow and who led this project. For other junior investigators, early-career investigators, how did you do this? How did you manage to do this, and how did you mentor Jessica on this project with some of the lessons that you learned along the way, the good and other things that would perhaps help other listeners as they try to mentor residents, trainees, which is one of the important things of what we do in our daily routine? Dr. Alissa Cooper: I appreciate you calling me accomplished. Um, I'm not sure how true that is, but I appreciate that. I didn't have to do a whole lot with this project because Jesse is an extraordinarily smart, driven, talented fellow who came up with a lot of the clinical questions and a lot of the research questions as well. And so this project was definitely a collaborative project on both of our ends. But I think what was helpful from both of our perspectives is from my perspective, I could kind of see that this was a gap in the literature that really, I think, from my work leading clinical trials and from treating patients with these kinds of cancers that I really hoped to answer. And so when I came to Jessica with this idea as sort of a project to complete, she was very eager to take it and run with it and also make it her own. You know, in terms of early mentorship, I have to admit this was the first project that I mentored, so it was a great learning experience for me as well because as an early-career clinician and researcher, you're used to having someone else looking over your shoulder to tell you, "Yes, this is a good journal target, here's what we can anticipate reviewers are going to say, here are other key collaborators we should include." Those kind of things about a project that don't always occur to you as you're sort of first starting out. And so all of that experience for me to be identifying those more upper-level management sort of questions was a really good learning experience for me. And of course, I was fantastically lucky to have a partner in Jesse, who is just a rising star. Dr. Jessica Ross: Thank you. Dr. Rafeh Naqash: Well, excellent. It sounds like the first of many other mentorship opportunities to come for you, Alissa. And Jessica, congratulations on your next step of joining and being faculty, hopefully, where you're training. Thank you again, both of you. This was very insightful. I definitely learned a lot after I reviewed the manuscript and read the manuscript. Hopefully, our listeners will feel the same. Perhaps we'll have more of your work being published in JCO PO subsequently. Dr. Alissa Cooper: Hope so. Thank you very much for the opportunity to chat today. Dr. Jessica Ross: Yes, thank you. This was great. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so as you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Disclosures: Dr. Alissa Jamie Cooper Honoraria Company: MJH Life Scienes, Ideology Health, Intellisphere LLC, MedStar Health, Physician's Education Resource, LLC,  Gilead Sciences, Regeneron, Daiichi Sankyo/Astra Zeneca, Novartis,  Research Funding: Merck, Roche, Monte Rosa Therapeutics, Abbvie, Amgen, Daiichi Sankyo/Astra Zeneca Travel, Accommodations, Expenses: Gilead Sciences

Dr Jonathan Strosberg from Moffitt Cancer Center in Tampa, Florida, discusses recent updates on available and novel treatment strategies for extrapulmonary neuroendocrine carcinoma. CME information and select publications here.

Featuring an interview with Dr Jonathan Strosberg, including the following topics: Overview of extrapulmonary neuroendocrine carcinoma (NEC) (0:00) Treatment strategies for extrapulmonary NEC (10:26) Targeting DLL3 in extrapulmonary NEC (18:49) Early clinical data with obrixtamig for extrapulmonary NEC (21:56) Additional investigational agents for extrapulmonary NEC (25:44) Case: A woman in her mid 50s with poorly differentiated metastatic NEC of unknown primary (27:20) Case: A man in his early 60s with poorly differentiated metastatic esophageal NEC (32:30) Clinical management of well-differentiated NEC (36:58) CME information and select publications  

Dr Jonathan Strosberg from Moffitt Cancer Center in Tampa, Florida, discusses recent updates on available and novel treatment strategies for extrapulmonary neuroendocrine carcinoma. CME information and select publications here.

Dr Jonathan Strosberg from Moffitt Cancer Center in Tampa, Florida, discusses recent updates on available and novel treatment strategies for extrapulmonary neuroendocrine carcinoma. CME information and select publications here.

Dr Jonathan Strosberg from Moffitt Cancer Center in Tampa, Florida, discusses recent updates on available and novel treatment strategies for extrapulmonary neuroendocrine carcinoma. CME information and select publications here.

Featuring a slide presentation and related discussion from Dr Jonathan Strosberg, including the following topics: Overview of the classification, grading and incidence of neuroendocrine carcinoma (NEC) (0:00) Overview of mutational profile, biomarker assessments and prognosis of NEC (3:45) Current treatment paradigm for extrapulmonary NEC (8:59) DLL3 as an emerging target biomarker in extrapulmonary NEC (17:46) Novel therapeutic agents under investigation for extrapulmonary NEC (23:05) CME information and select publications

In episode 56 of Going anti-Viral, Dr Steven Grinspoon joins host Dr Michael Saag to discuss managing cardiovascular health in people with HIV. Dr Grinspoon is a clinician in the Neuroendocrine and Pituitary Tumor Clinical Center and faculty member at the Massachusetts General Hospital, and a Professor of Medicine at Harvard Medical School. He is a clinical researcher who studies hypothalamic control of body weight and fat distribution in obesity and lipodystrophy with a focus on the metabolic and cardiovascular consequences of visceral fat accumulation. Dr Grinspoon provides an overview of cardiovascular disease in people with HIV including a review of the REPRIEVE study that evaluated if statin medication is effective to prevent heart disease among people with HIV. Dr Saag and Dr Grinspoon detail the REPRIEVE study results demonstrating that statins lower baseline low-density lipoprotein (LDL) cholesterol levels and discuss the cardiovascular health benefits of lowering LDL cholesterol levels. They discuss arterial plaque, how it is measured and whether plaque can regress individuals on statins. Finally, Dr Saag and Dr Grinspoon discuss goals for follow-up studies to REPRIEVE and other studies looking into the benefits of statins in other populations.0:00 – Introduction1:28 – Overview of cardiovascular disease in people with HIV 3:23 – Overview of the REPRIEVE study, which evaluated if statin medication is effective to prevent heart disease among people with HIV10:51 – REPRIEVE study results lowering baseline LDL cholesterol                       13:26 – Follow-up studies in people who do not have HIV16:20 – How plaque is measured in the arteries19:40 – Regression of plaque in patients using statins 21:15 – Top goals for follow-up studies to REPRIEVEResources: REPRIEVE Study: https://www.reprievetrial.org/ __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode, Dr. Daniel Morgensztern and Dr. Jonathan Strosberg discuss the emerging role of DLL3-targeted agents in the management of extrapulmonary neuroendocrine carcinomas, including:The clinical implications of using DLL3 as a therapeutic targetThe impact of emerging DLL3-targeted therapies on evolving treatment paradigmsHow to incorporate DLL3-based treatments into clinical practicePresenters:Daniel Morgensztern, MDProfessor of MedicineClinical Director of Thoracic OncologyWashington University School of MedicineSt Louis, MissouriJonathan Strosberg, MDProfessorDepartment of GI OncologyMoffitt Cancer Center and Research InstituteTampa, FloridaContent based on an online CME program supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Link to full program: https://bit.ly/4mjNPfy

In our conversation, Dr García-Carbonero discussed a subgroup analysis from the phase 3 FRESCO-2 trial (NCT04322539), which evaluated fruquintinib (Fruzaqla) in previously treated metastatic CRC (mCRC). She reviewed efficacy outcomes by metastatic site, including liver-only, lung-only, bone, and peritoneal disease. Fruquintinib demonstrated improvements in overall survival and progression-free survival across all subgroups, underscoring its feasibility in later-line settings for patients with mCRC. She also addressed prognostic differences between metastatic sites, noting that all patient groups derived benefit from treatment. Dr García-Carbonero also shared findings from PROMETCO, the first international, prospective, real-world study in mCRC, which is examining real-world outcomes for this patient population. 

“I'm not living the life I thought I would—but I *am* living. I'm no longer just existing. It's hard. It's painful. But it's real. This is my reality.”Nothing in my life feels "normal." There's no roadmap. Just the cards I've been dealt—and I'm learning to play them, even when the deck feels stacked against me.I've faced adversity that's shaped me into the person I am today. One moment that really stands out is being dismissed by a doctor when I raised concerns about breast cancer. That experience taught me a powerful lesson: "your gut is gold". You have to trust it—even when others won't listen.Key TakeawaysListen to your gut — It's there for a reason. Don't silence it to keep others comfortable.Take note of who shows up— When the sh*t hits the fan, you learn who's truly in your cornerBe your own advocate — Doctors are not gods. You know your body better than anyone."You do you” in health battles — There is no one-size-fits-all. Do what you need to survive, heal, or just make it through the day.Existing vs. Living — There's a world of difference. I've learned that choosing to "live"—even if it's messy or painful—is worth everything.allaboutyoupodcast@yahoo.comhttps://www.youtube.com/@allaboutyoupodcast2505

Summer Stack — The Best Supplement + Program Combos for Results Summer Stack — The Best Supplement + Program Combos for Specific Results. (1:31) #1 - For muscle mass: Whey protein + creatine. (4:51) Program: MAPS Anabolic #2 - For targeted sculpting: Essential amino acids (for calorie restriction), creatine, and whey protein. (10:21) Program: MAPS Symmetry  #3 - For mobility: Omega 3s + water. (17:19) Program: MAPS Prime Pro #4 - For athletic performance: Creatine, caffeine, and beetroot powder. (23:18) Program: MAPS Performance #5 - Stress reduction: Ashwagandha + magnesium. (27:00) Program: MAPS 15 #6 - Fat loss: Green tea extract (EGCG) + essential amino acids. (31:10) Program: MAPS HIIT Related Links/Products Mentioned Visit Our Place for an exclusive offer for Mind Pump listeners! **Promo code MINDPUMP at checkout to receive 10% off sitewide. Our Place offers a 100-day trial with free shipping and returns. ** Special Promotion: Summer Stack ** 50% off the selected MAPS programs using the code STACK at checkout. ** Mind Pump # 2497: The Amazing & Weird Side Effects of Creatine Mind Pump # 2432: The Truth About Essential Amino Acids with Angelo Keely Mind Pump # 1790: The Secret to an Attractive & Functional Body The Effect of Omega-3 Fatty Acids on Rheumatoid Arthritis Possible Effects of Beetroot Supplementation on Physical Performance Through Metabolic, Neuroendocrine, and Antioxidant Mechanisms: A Narrative Review of the Literature Visit Organifi for the exclusive offer for Mind Pump listeners! **Promo code MINDPUMP at checkout for 20% off** Therapeutic effect of high-dose green tea extract on weight reduction: A randomized, double-blind, placebo-controlled clinical trial Mind Pump Podcast – YouTube Mind Pump Free Resources  

Neuroendocrine tumors are rare and can present with a confusing range of symptoms, which leads to frequent misattribution. Jay Bart Rose, M.D., explains how they're also complex to treat, often requiring multiple modalities based on tumor location and hormone activity. He discusses surgery, systemic therapies, and PRRT, a targeted treatment that uses the same receptor pathway as specialized imaging. Learn how UAB's multidisciplinary neuroendocrine tumor clinic brings specialists together for long-term management.

When in one's neuroendocrine cancer journey might a clinical trial be considered? What factors influence treatment decisions, including whether to pursue a clinical trial? Dr. Alexandria Phan, medical oncologist at the Medical College of Wisconsin, offers thoughtful guidance on when and how clinical trials fit into the neuroendocrine cancer journey. This episode helps demystify the clinical trial process and empowers patients to engage in meaningful, proactive conversations with their care teams.MEET DR. ALEXANDRIA PHANDr. Alexandria Phan is a hematologist and medical oncologist at the Froedtert & Medical College of Wisconsin. Clinical practice, clinical research and education are three pillars important to Dr. Phan's approach to cancer care. Her areas of focus for clinical research and patient care are neuroendocrine tumors and malignancies of the gastrointestinal system. She has held several leadership positions, including cancer center director, founding program director for Hematology-Oncology fellowship, medical director of clinical research, and national director for GI cancer program.For more information, visit NCF.net.

In this episode of NETWise, we continue our focus on neuroendocrine carcinoma, a rare and aggressive form of neuroendocrine cancer. While our previous episode explored diagnosis and treatment, this discussion centers on the unique challenges faced by caregivers. Caring for someone with neuroendocrine carcinoma can be incredibly intense due to the cancer's rapid progression and […] The post NETWise Episode 47: Care for the Neuroendocrine Carcinoma Caregiver appeared first on NETRF.

In this episode of NETWise, we're diving into one of the more aggressive forms of neuroendocrine cancer: neuroendocrine carcinoma (NEC). While many neuroendocrine tumors are slow-growing and manageable over time, NEC is different—fast-moving and requiring swift, specialized care. We'll guide you through the essential information about NEC, including: What neuroendocrine carcinoma is and how it […] The post NETWise Episode 46: Understanding Neuroendocrine Carcinoma appeared first on NETRF.

In this video, I debunk all the recovery myths that keep you stuck. They might seem to work temporarily, but in the long run, they are a waste of your time. Whether you have long COVID, ME/CFS, Lyme, adrenal fatigue, chronic fatigue, fibromyalgia, or MCAS, this 20-minute video will save you years of time.Join our Q&A: https://releasecfs.com/contact/ Blog: https://releasecfs.com/developing-the-cfs-personality/Time Stamps: 00:59 The myth of the magic recovery moment 01:48 The myth of the baseline and pacing 03:40 The Cell Danger Response (CDR) by Dr. Robert Naviaux 04:22 Overcomplicating your recovery and healing journey 05:01 How to simplify your condition and understand different symptoms 07:15 The myth of the false danger response 07:44 The MindBody theory and lots of research 11:57 What is the best way to heal? 14:52 Myth - There is something wrong with your body (infections, immune system, genetics, mitochondria 16:42 The myth about Brain Retraining 19:04 Myth- Different things work for different people 19:46 The 4 steps to heal in the Release Program 21:13 Myth - Calming down the nervous system 21:36 Final Thoughts and tips.

This episode is part of a collaboration with the FlaNET Carcinoid Community, focusing on financial toxicity. We explore some of the major costs that can arise throughout the neuroendocrine cancer journey and share guidance on how to find helpful resources. NET specialists included in this episode Use our episode infographics to get a visual picture […] The post Managing the Financial Burden of Neuroendocrine Cancer appeared first on NETRF.

The episode features Dr. David Bartlett, a retired GP and neuroendocrine cancer patient, offering a dual perspective as both clinician and patient.Key Learnings from this episode.Patient Experience and Diagnostic ChallengesDr. Bartlett's symptoms began with severe, intermittent abdominal pain, starting in 2001, but he did not seek medical help for several years due to a combination of stoicism, not wanting to trouble others, and a belief in the commonality of benign causes. Over 15 years, he experienced repeated misdiagnoses, primarily being labeled as having irritable bowel syndrome (IBS) despite atypical features (severe pain, minimal bowel habit change, and no systemic symptoms). Multiple opinions and investigations (including ultrasounds and CT scans) failed to identify the underlying cause, with a key scan being misread by local radiologists. The correct diagnosis of a small bowel neuroendocrine tumour was only made after a tertiary centre re-examined previous scans, highlighting the importance of specialist review and persistence in unexplained cases.Clinical Red Flags and SymptomatologyDr. Bartlett's case underscores that neuroendocrine tumors can present with isolated, severe abdominal pain without classic red flags (vomiting, weight loss, significant bowel changes)[1]. He retrospectively identified subtle signs of carcinoid syndrome (flushing, one episode of profound diarrhoea, and skin changes), which are present in only about 10% of small bowel neuroendocrine tumour cases. The lack of awareness about neuroendocrine tumors, even among experienced clinicians, contributed to the diagnostic delay[1].Lessons for Primary Care and CliniciansThe story illustrates the risk of anchoring on common diagnoses (like IBS) and the need to reconsider the diagnosis when symptoms are severe, persistent, or atypical. It highlights the value of listening to the patient's narrative, especially when symptoms do not fit classic patterns, and the importance of considering rare conditions in the differential diagnosis. The episode emphasises the need for ongoing education about neuroendocrine tumours and the importance of keeping rare but serious conditions on the diagnostic radar in primary care.Management InsightsStandard treatment for small bowel neuroendocrine tumours often includes monthly somatostatin analog injections (e.g., lanreotide). Surgical intervention may be considered, but it carries specific risks such as carcinoid crisis, requiring specialised perioperative management. The decision for surgery is individualised, weighing potential symptomatic improvement against procedural risks.Systemic and Human FactorsDr. Bartlett's experience reflects how personal traits (stoicism, reluctance to seek help) and systemic issues (misinterpretation of scans, diagnostic inertia) can delay diagnosis. The narrative also demonstrates the importance of patient advocacy, persistence, and the value of second (or third) opinions, especially in complex or unresolved cases.Educational ValueThe episode serves as a reminder for clinicians to maintain a broad differential, revisit diagnoses when the clinical picture changes, and to be aware of their own cognitive biases. It also advocates for the inclusion of patient voices in medical education to better understand the lived experience and challenges of rare diseases like neuroendocrine cancer.Summary Table: Key LearningsThemeKey PointsDiagnostic Delay15 years from symptom onset t... Chapters (00:00:10) - Ingest(00:02:07) - David Bartlett on neuroendocrine cancer(00:05:32) - Irritable bowel syndrome, 15 years after first bout(00:12:09) - Carcinoid syndrome in small bowel neuroendocrine tumors(00:16:10) - Neuroendocrine tumour, surgery and recovery(00:20:43) - Somaostatin analogues for neuroendocrine cancer(00:25:43) - The role of the multidisciplinary team in bowel cancer care(00:28:21) - The battle with depression in your 50s(00:30:00) - General Practice and the Art of Medicine(00:33:13) - General Practice: The challenge of slowing down(00:35:35) - Neuroendocrine Cancer UK support group(00:39:28) - David's story of cancer(00:40:38) - David's Neuroendocrine Cancer Episode 1

In this special episode, medical oncologist and NET expert Dr. Diane Reidy-Lagunes engages in an open and honest discussion on sensitive topics, including sexual health, family planning and end-of-life discussions. She also answers common questions regarding cannabis use with cancer, as well as the relationship between sugar and cancer. Dr. Reidy shares information and insights from her decades of experience as well as from the award-winning “Cancer Straight Talk” podcast from Memorial Sloan Kettering Cancer Center (MSKCC) that she created and hosted, and she relates these topics to NET patients and their loved ones.TOP TEN QUESTIONS What is cancer? Is NET cancer?Should I follow a certain diet? Does sugar feed cancer? Can I exercise if I have metastatic neuroendocrine cancer?What does having neuroendocrine cancer mean for my romantic life? How does it affect dating?What does having neuroendocrine cancer mean for my sexual health?What does having neuroendocrine cancer mean for fertility and family planning? Can I have children?How do I talk to my kids about cancer?How will I know when it's time for end-of-life discussions?Should I consider cannabis?What advice do you have about improving communication with my doctor?For more information, visit LACNETS.org.

What is Carcinoid Heart Disease (CHD)? Which NET patients develop CHD?  Retired cardiologist and carcinoid heart disease specialist Dr. Jerome Zacks provides an overview of CHD and describes the appropriate screening, diagnosis, and treatment. MEET DR. JEROME ZACKSDr. Jerome Zacks is a Cardiologist/Carcinoid Heart Disease Specialist; retired since December of 2021; but remain active as Associate Clinical Professor of Medicine at the Icahn Medical School at Mount Sinai in New York City and founding member of the Center for Carcinoid and Neuroendocrine Tumors at the Icahn Medical School at Mount Sinai; founder of the Carcinoid Heart Center; formerly on the Medical Advisory Board of the Carcinoid Cancer Foundation;  currently head the Electrocardiography course for the 4th Year Medical Student elective at the Mt. Sinai Medical Center which has resulted in an international reputation among students seeking Cardiology training in the United States.  He has expertise in matters of health care Insurance Carriers' theft of funds from the Medicare program, has studied patterns of abuse in the Medicaid program and has extensive knowledge of pharmaceutical company abusive practices. Dr. Zacks continues to devote time to the care of patients with Carcinoid Heart Disease. He has served as a member of the Guidelines Committees of the European Neuroendocrine Tumor Society (ENETS) and of the North American Neuroendocrine Tumor Society (NANETS).   He developed a new approach to compression stockings for patients with leg edema; he was granted a patent for this innovation.  He has authored two national petitions urging Congress to mandate that any health care professional who uses one's license, in making decisions which influence a patient's care, be held to the SAME STANDARD OF CARE as the patient's treating professional. (These two petitions were blocked by Senator Cory Booker.)  In his role as patients' physician, he has attempted to remove barriers of communication.  His business card includes his personal mobile phone number as well as his email address and website information; He encourages patients to phone for immediate answers to urgent matters.  Along with his wife, Yelena - an RN- they have devoted their professional lives to patients with heart disease from rare Neuroendocrine tumors. They have mentored 5 children, and are now learning from them and their 6 grandchildren have provided the real fuel and excitement for their lives.For more information, visit https://www.ncf.net/podcast/43For more information, visit LACNETS.org.

Artificial intelligence (AI) has become a hot topic, making its way into everyday conversations and industries worldwide. While AI technologies have been around for years, recent advancements are accelerating their impact—especially in healthcare. From improving cancer research to enhancing diagnosis and treatment, AI is reshaping the future of medicine. In this episode of NETWise, we […] The post NETWise Episode 43: How Could AI Change Neuroendocrine Cancer? appeared first on NETRF.

Happiness is something that can be difficult to find in life, no matter what. Having an uncommon cancer can make it infinitely harder. The post NETWise Episode 42: Finding Happiness While Living with Neuroendocrine Cancer appeared first on NETRF.

Sol Wertkin is a former rock climber, cancer survivor, nurse, and avid mountain biker. We talked about new routing in the PNW, the “Golden Era” of Leavenworth climbing, the passing of Johnny Goicoechea, Sol's cancer diagnosis in 2020, the long and difficult road to recovery, how e-biking saved his life, sailing, why life feels richer now that he doesn't climb, and nuggets to help your own health journey.Feel free to message Sol on Instagram if you have any questions about cancer diagnosis or long covid. AG1:drinkAG1.com/NUGGETUse this link to get a free year's supply of vitamin D + 5 travel packs.Arc'teryx:Women's climbing clothingMen's climbing clothingCheck out the Psiphon and Serratus Alpine Kits launching January 15th.Rúngne:rungne.info/nugget

From the elusive neuroendocrine tumours like Rathke's Cleft Cysts and pituitary gland tumours to the broader impacts these conditions have on daily life, we explore it all. Join us as we navigate through the complexities of the body's inner workings, discuss the latest medical research, and hear firsthand accounts from those on the front lines of their own medical journeys. Whether you're a medical professional, a patient, or simply curious about the oddities of human biology, The Mutation Station offers insights and inspiration for everyone. Tune in to discover more about the mysteries of the human body and the resilience of the human spirit.

ABOUT THIS EPISODEWhat is radiation oncology, and how is it used for neuroendocrine cancer? UCSF radiation oncologists Dr. Will Chen and Dr. Alexandra Hotca-Cho describe external radiation therapy (SBRT) and how, when, and where it may be used for select patients with neuroendocrine cancers. They address common concerns about the planning process, safety concerns, and treatment sequencing.TOP TEN QUESTIONS ABOUT EXTERNAL RADIATION THERAPY FOR NEUROENDOCRINE CANCERS:1. What is radiation oncology? How does it work? How is it different from other types of radiation?2. What are the types of radiation therapies used for neuroendocrine cancer? 3. Which neuroendocrine cancers are they used for, and when are they used? How do you decide who is a good candidate and if it will be effective?Where in the body can SBRT be used? (bone, liver, pancreas, rectal?) Where can it not be used in the body, and when is SBRT NOT used?Is there a number or size limit of the tumor(s)?4. For Bone: How do NETs affect the bones? Are they “on” or “in” the bone, and does the tumor tend to weaken it?If given to the bone, does SBRT weaken the bone? What are the chances of fracture with radiation to the bone? Does it matter which area of the bone/body is treated? What other factors influence fracture risk? (age, dose, number of treatments)? Should patients have a bone density scan before SBRT?If bone lesions are causing pain, how soon after treatment might a patient expect to have pain alleviated?How common is increased pain after treatment to the bone? What causes that?5. Safety: How much radiation is given with these procedures? Is there a concern about radiation safety following the procedures? (Do patients need to avoid others in the hours or days after the treatment?)Is there a lifetime limit to the amount of radiation one can receive, especially considering surveillance CT & PET scans?How often can these procedures be repeated? Does it damage other tissues or organs? How common are secondary cancers? What types and how treatable are they?Is there a risk with fertility?What other risks are there?6. How do these therapies compare to PRRT or radioembolization in terms of safety? If someone has had PRRT or radioembolization, can they also receive radiation therapy to the liver or bones? Is there increased risks if someone has had PRRT, radioembolization or CAPTEM or alkylating agents? 7. Is there an optimal sequence for treatments? 8. What is SBRT like for patients? What is the planning and preparation process? How do you determine how many treatments and what dose to give?9. What does the patient experience during and after the procedure? Does it hurt? What are the side effects? How much time do I need to take off of work? 10. How effective is SBRT in terms of managing symptoms? How effective is SBRT in controlling or destroying the tumor?  How do you know if the treatment “worked”?Bonus: What is the future of radiation therapy in neuroendocrine cancer treatment?For more information, visit LACNETS.org.

My guests today are Laney and Bridgette Casey. Last year I interviewed their parents, Matt and Celeste. Over three years ago Matt was diagnosed with an extremely rare illness called Neuroendocrine cancer. It almost took his life and so often so much of the attention, although well deserved, goes to the person suffering. Often times the family can sometimes get overlooked even as they are suffering along side the sick or injured one. This is Matt's story through THEIR eyes. The eyes of the children. Have your tissues handy. Listen to Matt and Celeste's original story here https://podcasts.apple.com/us/podcast/parrish-the-thought/id1348128086?i=1000636743479 #NeuroendocrineCancer #CancerSucks #FamilyFirst #NetCancer #ZebraStrong #CancerCard  #CaseyFamily

Neuroendocrine tumors have a multitude of different names, including carcinoid disease, carcinoid syndrome neuroendocrine tumor, and neuroendocrine neoplasia. Join Chris Curry as he learns about these 'zebra' tumors, and why they can be so difficult to diagnose .

Simron Singh, MD, MPH - Addressing the Challenges of Treating Highly Proliferative Neuroendocrine Tumours: Review of the Latest Evidence

Simron Singh, MD, MPH - Addressing the Challenges of Treating Highly Proliferative Neuroendocrine Tumours: Review of the Latest Evidence

What is supportive care or supportive oncology? What is cancer-related distress? How might NET patients benefit from supportive care? Yale oncologist Dr. Maryam Lustberg suggests strategies to manage cancer-related fatigue, diarrhea, nausea, mouth sores, peripheral neuropathy, distress, anxiety, and anxiety. She also addresses considerations for fertility and sexual health.MEET DR. MARYAM LUSTBERGDr. Maryam Lustberg is an American breast oncologist. She is the Director of The Breast Center at Smilow Cancer Hospital and Chief ofBreast Medical Oncology at Yale Cancer Center. Dr. Lustberg previously served as the Medical Director of Cancer Supportive Care Services atOhio State's Comprehensive Cancer Center. She is the Immediate Past President of the Multinational Association of Supportive Care in Cancer. She is also an Associate Editor for the Journal of Cancer Survivorship.TOP TEN QUESTIONS ABOUT SUPPORTIVE CARE: What is supportive care in cancer (or supportive oncology)? What is survivorship? How do these concepts apply to the NET community?What is the 1st step for patients to get supportive care?What are the most common treated-related adverse events or side effects? What are risk factors for them? (Will all patients experience all potential side effects?)What causes cancer-related fatigue (CRF)? What are some strategies to manage cancer-related fatigue?What are some strategies to manage diarrhea?What are some strategies to manage nausea?What are some strategies to manage mouth sores?What is peripheral neuropathy? When do patients experience it and what can be done to prevent it?What should patients understand about sexual health and fertility?How can psychosocial needs such as distress, anxiety, and depression be addressed and supported?For more information, please visit https://www.lacnets.org/podcast/37. For more information, visit LACNETS.org.

Send us a Text Message.SummaryIn this episode of the Next Level Human Podcast, Dr. Teta interviews Megan Lyons, a nutrition consultant, about the neuroendocrine-immune system and its impact on overall health. They discuss the effects of stress, exercise, and nutrition on the body, as well as the symptoms and signs of neuroendocrine dysfunction. Megan shares her personal journey of overcoming adrenal hormonal dysfunction and how it led her to focus on real nutrition. They also explore the role of the hypothalamus in regulating the endocrine system and the importance of addressing the root causes of dysfunction. In this conversation, Megan Lyons and Jade Teta discuss the role of testing in functional medicine and the complexity of interpreting test results. They also explore the importance of gut health and the impact of childhood development on the nervous system. They touch on the connection between thoughts, feelings, and the neuroendocrine-immune system and the potential for mind-body practices to improve health outcomes. Megan shares her personal experience with trauma and its impact on her nervous system, highlighting the need for a holistic approach to healing.Keywordsneuroendocrine-immune system, stress, exercise, nutrition, adrenal hormonal dysfunction, hypothalamus, root causes, functional medicine, testing, gut health, nervous system, childhood development, trauma, neuroendocrine-immune system, mind-body practicesChapters00:00- Introduction and Overview05:41- Personal Journey: Overcoming Adrenal Hormonal Dysfunction08:28- The Impact of Stress, Exercise, and Nutrition13:30- The Role of the Hypothalamus in Neuroendocrine Regulation16:45- Recognizing Symptoms of Neuroendocrine Dysfunction19:07- Addressing Root Causes for Restoring Balance24:08- The Complexities of Testing in Functional Medicine25:56- The Importance of Gut Health in Overall Well-being33:46- The Connection Between Thoughts, Feelings, and Health45:28- Taking a Holistic Approach to Healing Connect with Next Level HumanWebsite: www.nextlevelhuman.comsupport@nextlevelhuman.comConnect with Dr. Jade TetaWebsite: www.jadeteta.comInstagram: @jadeteta

#192 In this episode of 'Chemistry for Your Life,' hosts Melissa and Jam introduce special guest Claire Caballero, a pharmacology and neuroscience PhD student, to discuss how antidepressants work. Claire explains the role of neurotransmitters like serotonin, dopamine, and GABA in mental health, the mechanisms of various antidepressants such as SSRIs, tricyclic antidepressants, and monoamine oxidase inhibitors, and touches on the effects and side effects of drugs like Wellbutrin. The episode provides an insightful look at the chemistry and neuroscience behind how these medications help manage depression and anxiety. 00:00 Introduction and Special Guest Announcement 00:52 Meet Claire: Our Expert in Pharmacology and Neuroscience 01:32 Understanding Pharmacology and Neurotransmission 05:16 The Role of Neurotransmitters in Anxiety and Depression 14:16 Deep Dive into Neurotransmitters: GABA, Dopamine, and Serotonin 17:10 Exploring the Mechanisms of Depression and Anxiety 22:21 Ready to Learn About Antidepressant Drugs? 33:20 Understanding SSRIs and Their Uses 34:14 How SSRIs Work in the Brain 36:23 Challenges and Side Effects of SSRIs 43:08 Exploring Tricyclic Antidepressants 48:35 Monoamine Oxidase Inhibitors: The First Antidepressants 54:59 Benzodiazepines: Uses and Risks 01:00:01 Other Notable Drugs: Bupropion and Beta Blockers 01:05:07 Conclusion and Final Thoughts   References from this episode: https://www.ncbi.nlm.nih.gov/books/NBK554406/ https://www.ncbi.nlm.nih.gov/books/NBK557791/ https://www.ncbi.nlm.nih.gov/books/NBK539848/ https://www.ncbi.nlm.nih.gov/books/NBK470159/#:~:text=Benzodiazepines%20are%20effective%20for%20sedation,potential%20to%20develop%20physical%20dependence. https://www.nami.org/about-mental-illness/mental-health-conditions/anxiety-disorders/#:~:text=Anxiety%20disorders%20are%20the%20most,develop%20symptoms%20before%20age%2021. https://mhanational.org/conditions/depression#:~:text=Major%20depression%20is%20one%20of,are%20affected%20by%20major%20depression. https://www.cdc.gov/nchs/products/databriefs/db377.htm https://www.ncbi.nlm.nih.gov/books/NBK470212/ https://www.jneurosci.org/content/28/28/7040 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303399/ https://www.ncbi.nlm.nih.gov/books/NBK551683/#:~:text=Anxiety%20disorders%20such%20as%20panic,with%20decreased%20levels%20of%20GABA. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684250/#:~:text=Neuroendocrine%20and%20Neurotransmitter%20Pathways&text=Well%2Ddocumented%20anxiolytic%20and%20antidepressant,of%20mood%20and%20anxiety%20disorders. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950973/#:~:text=The%20monoamine%2Ddeficiency%20theory%20posits,in%20the%20central%20nervous%20system. https://www.health.harvard.edu/depression/depression-chemicals-and-communication https://www.ncbi.nlm.nih.gov/books/NBK539894/ https://www.sciencedirect.com/science/article/pii/S1476179306700246?via%3Dihub https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4610616/ We want to give a special thanks to Bri McAllister for illustrating molecules for some episodes! Please go check out Bri's art, follow and support her at entr0pic.artstation.com and @McAllisterBri on twitter!   Thanks to our monthly supporters Scott B Jessie Reder Ciara Linville J0HNTR0Y Jeannette Napoleon Cullyn R Erica Bee Elizabeth P Sarah Moar Rachel Reina Letila Katrina Barnum-Huckins Suzanne Phillips Venus Rebholz Lyn Stubblefield Jacob Taber Brian Kimball Emerson Woodhall Kristina Gotfredsen Timothy Parker Steven Boyles Chris Skupien Chelsea B Bri McAllister Avishai Barnoy Hunter Reardon ★ Support this podcast on Patreon ★ ★ Buy Podcast Merch and Apparel ★ Check out our website at chemforyourlife.com Watch our episodes on YouTube Find us on Instagram, Twitter, and Facebook @ChemForYourLife

Neuroendocrine neoplasms (NENs) can arise in many locations throughout the body; they can grow rapidly; and they can occur under unique circumstances. In this episode of NETWise, we talk through some of the more uncommon locations – and situations – where neuroendocrine neoplasms arise. This episode is devoted to some of those more uncommon situations. […] The post NETWise Episode 37: Uncommon Neuroendocrine Neoplasms (NENs) appeared first on NETRF.

Have you ever wondered why weight management seems like an uphill battle? In this episode, I dive deep into the topic of weight management and the role of the neuroendocrine system. Discover how our hormones play a crucial role in weight regulation and why traditional weight loss approaches often fall short.   Join me as I discuss the impact of modern lifestyle on our hormones, the rise of obesity, and the pharmaceutical arms race in the quest for weight loss solutions. Learn about medications like ozempic and semaglutide and their effects on weight loss, alongside the importance of holistic approaches to address weight loss resistance.   If you're ready to unlock the secrets of sustainable weight management, understand the influence of processed foods on our endocrine system, and gain practical tips for achieving a healthy weight, this episode is a must-listen. Tune in now for valuable insights and strategies to conquer weight challenges in today's world.   And hey, speaking of unlocking secrets, don't forget to grab your FREE E-book, "A Woman's Guide to Kick-Ass Sleep." If you're over 40 and struggling with sleep, this E-book is tailored just for you. Visit https://bit.ly/4cblYcT to download your copy and embrace rejuvenating sleep nights starting tonight. Key Takeaways: [00:02:10] Struggling with weight loss efforts. [00:06:03] Neuroendocrine system and weight management. [00:10:01] Incretin hormones affecting food intake. [00:14:18] Lifestyle drugs and weight regain. [00:16:27] Impact of processed foods on health. [00:21:39] Endocrine disruption in daily products. [00:25:30] Whole foods focused. [00:29:16] Root cause of weight issues. Memorable Quotes: "You have a recipe for weight loss resistance that had nothing to do with your ability to control what you can eat and to control how much you exercise. Because again, it's not a simple bank account of calories in calories out. These hormones will supersede what your body is up to." – Betty Murray   "The weight is not the problem. It is a symptom of the problem. And that's the ultimate root cause answer that you need to understand." – Betty Murray Links Mentioned: FREE E-Book: https://bit.ly/4cblYcT   Connect with Betty Murray: Living Well Dallas Website: https://www.livingwelldallas.com/ Hormone Reset Website: https://hormonereset.net/ Betty Murray Website: https://www.bettymurray.com/ Facebook: https://www.facebook.com/BettyAMurrayCN/ Instagram: https://www.instagram.com/bettymurray_phd/  

Today Maria opens up about her recent cancer & health journey and answers all of your burning questions! She shares about her initial symptoms, the scan she received that led to her diagnosis, and how she healed and recovered. She also shares the best advice on how to be the CEO of your health and truly advocate for yourself!  WE talk: -Maria's in-depth symptoms -How and why she got the Prenuvo scan  -Maria's surgery & hospital stay -Why googling your symptoms may actually be a good thing -What to do when you don't feel heard by your doctor -Why we have to prioritize our health -What Maria's energy healers told her through the process -Getting healthy for the arrival of her baby -How Maria stayed so strong throughout -Neuroendocrine vs. pancreatic cancer -Prenuvo scan giveaway & discount code  To get a $300 discount to the price of a whole body scan across current locations (LA, SF, NYC, Dallas, Boca Raton, Chicago and Minneapolis) and upcoming (Boston, DC and Atlanta) US locations go to: prenuvo.com/Maria (full link must be clicked and discount is automatically applied) For over the phone bookings: Simply mention the code Maria  HEAL SQUAD SOCIALS IG: @HealSquad TikTok: @HealSquadxMaria APPLE PODCASTS: https://podcasts.apple.com/us/podcast/heal-squad-x-maria-menounos/id1320060107 SPOTIFY: https://open.spotify.com/show/2kXrmaNDQQ4i6prZe6LO89?si=19af23c6154943d0 HEAL SQUAD RESOURCES: Website: www.mariamenounos.com Curated Macy's Page: macys.com/healsquad Amazon Storefront: https://www.amazon.com/shop/mariamenounos Patreon: https://patreon.com/HealSquad?utm_medium=clipboard_copy&utm_source=copyLink&utm_campaign=creatorshare_creator&utm_content=join_link ABOUT MARIA MENOUNOS: Emmy Award-winning journalist, TV personality, actress, 2x NYT best-selling author, former pro-wrestler and brain tumor survivor, Maria Menounos' passion is to see others heal and to get better in all areas of life. ABOUT HEAL SQUAD x MARIA MENOUNOS: A daily digital talk-show that brings you the world's leading healers, experts, and celebrities to share groundbreaking secrets and tips to getting better in all areas of life. DISCLAIMER: This Podcast and all related content [published or distributed by or on behalf of Maria Menounos or Mariamenounos.com] is for informational purposes only and may include information that is general in nature and that is not specific to you. Any information or opinions expressed or contained herein are not intended to serve as or replace medical advice, nor to diagnose, prescribe or treat any disease, condition, illness or injury, and you should consult the health care professional of your choice regarding all matters concerning your health, including before beginning any exercise, weight loss, or health care program. If you have, or suspect you may have, a health-care emergency, please contact a qualified health care professional for treatment. Any information or opinions provided by guest experts or hosts featured within website or on Company's Podcast are their own; not those of Maria Menounos or the Company. Accordingly, Maria Menounos and the Company cannot be responsible for any results or consequences or actions you may take based on such information or opinions.